alendronate has been researched along with Hyperphosphatemia in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Hyperphosphatemia: A condition of abnormally high level of PHOSPHATES in the blood, usually significantly above the normal range of 0.84-1.58 mmol per liter of serum.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the present study, we aimed to examine the efficacy and safety of alendronate (ALN) and teriparatide (TPD) for treating bone disorder in late-stage CKD with pre-existing secondary hyperparathyroidism using a rat model of CKD." | 3.85 | Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia. ( Hamano, H; Hiratsuka, S; Iwasaki, N; Kameda, Y; Kanehira, Y; Kimura-Suda, H; Ota, M; Sato, D; Shimizu, T; Takahata, M, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ota, M | 1 |
| Takahata, M | 1 |
| Shimizu, T | 1 |
| Kanehira, Y | 1 |
| Kimura-Suda, H | 1 |
| Kameda, Y | 1 |
| Hamano, H | 1 |
| Hiratsuka, S | 1 |
| Sato, D | 1 |
| Iwasaki, N | 1 |
| Iglesias, P | 1 |
| Castro, JC | 1 |
| Abreu, C | 1 |
| Díez, JJ | 1 |
2 other studies available for alendronate and Hyperphosphatemia
| Article | Year |
|---|---|
Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Disease Models, Animal; Dru | 2017 |
[Long-term combined treatment with cinacalcet and bisphosphonates in persistent primary hyperparathyroidism after surgery].
Topics: Alendronate; Bone Density Conservation Agents; Cinacalcet; Drug Therapy, Combination; Female; Humans | 2012 |